Ozempic vs Mounjaro
The two most prescribed GLP-1 medications compared by brand. Which is better for weight loss, and what your doctor won't tell you about off-label use.
Ozempic
- Generic Name
Semaglutide - Manufacturer
Novo Nordisk - FDA Indication
Type 2 Diabetes - Weight Loss Use
Off-label (Wegovy = approved) - Mechanism
GLP-1 receptor agonist - Max Dose
2 mg/week (Ozempic) - Key Trial
STEP 1: 14.9% weight loss - Cost (Cash)
$900–$1,200/mo
Mounjaro
- Generic Name
Tirzepatide - Manufacturer
Eli Lilly - FDA Indication
Type 2 Diabetes - Weight Loss Use
Off-label (Zepbound = approved) - Mechanism
Dual GLP-1/GIP agonist - Max Dose
15 mg/week - Key Trial
SURMOUNT-1: 22.5% weight loss - Cost (Cash)
$1,000–$1,200/mo
Key Distinction: Brand Names vs Active Ingredients
This is where most people get confused. Ozempic and Wegovy are both semaglutide: same drug, different doses and FDA approvals. Mounjaro and Zepbound are both tirzepatide — same relationship. Ozempic is technically for diabetes; many doctors prescribe it off-label for weight loss because Wegovy has been harder to get.
Weight Loss Comparison
Important Context
Ozempic's max dose is 2 mg (for T2D). Wegovy goes up to 2.4 mg (for weight loss). The STEP 1 trial used the 2.4 mg Wegovy dose. If you're on Ozempic at 1–2 mg for weight loss, your results may differ from the trial numbers above.
Side Effects
Insurance & Access
This is often the deciding factor for most patients:
- Insurance coverage varies widely. Some plans cover Ozempic but not Mounjaro, or vice versa. Check your formulary first.
- Manufacturer savings cards from both Novo Nordisk and Eli Lilly can bring copays to $25/month for eligible commercially insured patients.
- Compounded semaglutide has been available through telehealth at ~$150–$400/month. FDA compounding rules have been shifting; check current availability.
- Supply shortages have affected both brands intermittently since 2023. Mounjaro supply has generally been more stable.
Who Should Choose What?
- Your insurance covers it and not Mounjaro
- You want an oral option (Rybelsus) — no oral tirzepatide yet
- Compounded semaglutide is available and cost is your main concern
- You prefer the longer safety track record
- Maximum weight loss is your priority
- You've plateaued on semaglutide
- GI side effects concern you (tirzepatide may be gentler)
- Your insurance covers it, or you can access Zepbound
If cost and access are equal, Mounjaro/tirzepatide edges out on efficacy. If you're paying cash, compounded semaglutide may be the most affordable path. Work with your doctor and check your insurance first. The "best" drug is the one you can actually get and afford consistently.
Frequently Asked Questions
Clinical data suggests tirzepatide (Mounjaro) produces greater weight loss — 22.5% vs 14.9%. The SURMOUNT-5 head-to-head trial confirmed tirzepatide's superiority. However, both are effective and individual results vary.
Ozempic is FDA-approved for type 2 diabetes, not weight loss, but doctors frequently prescribe it off-label. Wegovy is the same drug (semaglutide) at a higher dose, approved for weight loss.
Without insurance: Ozempic ~$900–$1,200/mo, Mounjaro ~$1,000–$1,200/mo. With insurance, copays vary from $0–$300/mo. Both have manufacturer savings programs.
Both cause GI side effects: nausea, diarrhea, vomiting, constipation. Mounjaro may have slightly lower nausea rates. Both carry boxed warnings for thyroid C-cell tumors.
Yes, with your doctor's guidance. Start Mounjaro at its lowest dose (2.5 mg) after stopping Ozempic. Many patients switch when they plateau.
Recommended Products
Support your GLP-1 weight loss journey
Affiliate links support HighPeptides at no extra cost.
Related Comparisons & Tools
Explore more GLP-1 resources